Literature DB >> 35641275

Large Tumor Size and High Neutrophil-to-lymphocyte Ratio Predicts Poor Prognosis After Pneumonectomy or Sleeve Lobectomy in Patients With Non-small-cell Lung Cancer.

Takuma Tsukioka1, Nobuhiro Izumi2, Hiroaki Komatsu2, Hidetoshi Inoue2, Ryuichi Ito2, Satoshi Suzuki2, Noritoshi Nishiyama2.   

Abstract

BACKGROUND/AIM: The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are useful biomarkers in non-small cell lung cancer (NSCLC). The aim of this study was to identify novel prognostic factors after pneumonectomy or sleeve lobectomy. PATIENTS AND METHODS: The clinical courses of 68 patients with NSCLC who underwent pneumonectomy or sleeve lobectomy were retrospectively investigated.
RESULTS: High NLR (p=0.002) and PLR (p=0.006), and large tumor (>40 mm) (p=0.024) were indicative of poor prognosis in univariate analysis. High NLR (p=0.021) and large tumor (>40 mm) (p=0.017) remained independent factors indicating poor prognosis in multivariate analysis. Eighteen patients with both high NLR and large tumor (>40 mm) had significantly poorer prognoses than the remaining patients, 10 of them having recurrences within a short time after surgery.
CONCLUSION: A high NLR and large tumor size indicate a poor prognosis after pneumonectomy or sleeve lobectomy. Our findings may be helpful in selecting optimal treatments for this subgroup of patients.
Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Non-small cell lung cancer; neutrophil-to-lymphocyte ratio; platelet-to-lymphocyte ratio; pneumonectomy; sleeve lobectomy

Mesh:

Year:  2022        PMID: 35641275     DOI: 10.21873/anticanres.15788

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Elevation of Neutrophil-to-Lymphocyte Ratio Is a Significant Poor Prognostic Factor in Completely Resected Centrally Located Lung Squamous Cell Carcinoma.

Authors:  Takuma Tsukioka; Nobuhiro Izumi; Hiroaki Komatsu; Hidetoshi Inoue; Ryuichi Ito; Satoshi Suzuki; Noritoshi Nishiyama
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.